Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGenincode Regulatory News (GENI)

Share Price Information for Genincode (GENI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 5.70
Bid: 5.40
Ask: 6.00
Change: 0.00 (0.00%)
Spread: 0.60 (11.111%)
Open: 5.70
High: 5.70
Low: 5.70
Prev. Close: 5.70

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

British Medical Journal publication

3 Nov 2022 07:00

RNS Number : 1412F
03 November 2022

GENinCode Plc

("GENinCode" or the "Company")


British Medical Journal publication

Study on Avoiding Late Diagnosis of Ovarian Cancer ("ALDO")


Oxford, UK. GENinCode Plc (AIM: GENI), the predictive genetics company focused on the prevention of cardiovascular disease ("CVD") and risk of ovarian cancer ("OC"), announces jointly with the British Medical Journal ("BMJ"), the ALDO publication in the Journal of Medical Genetics. ALDO is an NHS national pilot surveillance programme for women with pathogenic germline variants in BRCA1 and BRCA2 inherited genes. The results showed that surveillance of OC using the ROCA Test down-stages OC, leading to a high complete tumour removal rate which improves outcomes for patients, and is cost-saving in an NHS setting. The ROCA Test is a blood test that assesses a woman's risk of having ovarian cancer. The results concluded that whilst preventative surgery remains the recommended route for BRCA mutation positive women, the ROCA-based surveillance test may be considered a short-term option for women deferring such surgery.


The ALDO project is a partnership between the North Central London Cancer Alliance, and Abcodia Ltd (now owned by GENinCode Plc). The partnership was formed in 2017 as part of an NHS-industry challenge to improve the early diagnosis of cancer. The project set an objective of establishing further clinical evidence for the performance and cost-effectiveness of OC surveillance using the ROCA Test, in women with pathogenic BRCA1/2 variants who had deferred risk-reducing surgery. The proprietary algorithm calculates a woman's individual OC risk based on a number of factors including cumulative CA 125 blood test results, age, menopausal status and the presence of a BRCA1 or BRCA2 gene mutation. The CA 125 blood test is a widely available across global healthcare systems offering the prospect of easy adoption of the algorithm.


875 female BRCA1/2-heterozygotes were recruited through 13 UK NHS genetic centres, or via an online media campaign, with 767 women undergoing at least one four-month surveillance with the ROCA Test. Abnormal ROCA results referred women for repeat ROCA Testing or a Transvaginal Ultrasound Scan (TVUS). Surveillance performance was calculated by assessing the presence of OC confirmed at surgery. In an economic analysis, the incremental cost-effectiveness ratio ("ICER") was also calculated.


During the pilot study, conducted over a 30-month period, eight OC cases were identified. Six cases were detected by the ROCA Test and two cases were detected at the point of self-opted risk reducing surgery. Three of the six (50%) surveillance-detected OC cases were confirmed through surgery at stages where there was no visible disease beyond the pelvis. A complete surgical removal of the tumour was possible in five of six (83%) cases. Modelled sensitivity, specificity, PPV and NPV for OC were 87.5% (95%CI, 47.3-99.7), 99.9% (99.9-100), 75% (34.9-96.8) and 99.9% (99.9-100) respectively. The predicted number of quality-adjusted life-years gained by surveillance was 0.179 with an ICER cost-saving of -£102,496/QALY.


The results showed that OC surveillance for women deferring RRSO in a 'real-world' setting is feasible and demonstrated similar performance to the earlier research trials. Surveillance down-stages OC, which enables a more complete cytoreduction, therefore improving patient outcomes and is cost-saving in the UK setting. Whilst preventative surgery remains recommended management for preventing OC, surveillance with the ROCA Test can be considered as a short-term option for BRCA-heterozygotes deferring such surgery.


Click https://www.bmj.com/company/newsroom/ovarian-cancer-surveillance-in-women-with-faulty-brca-genes-results-in-earlier-stage-diagnosis/ to read the press release from the BMJ.

Matthew Walls, Chief Executive Officer of GENinCode Plc said: "Following the recent acquisition of the Abcodia business and ROCA Test, we are delighted with today's publication and the BMJ announcement of the positive ALDO outcome. Importantly, we hope that this publication will support NICE as it continues with its development of comprehensive guidance for women at risk of or suffering from familial ovarian cancer and enable the NHS to take advantage of the forecast cost saving benefits."


For more information visit www.genincode.com


GENinCode Plc

www.genincode.com or via Walbrook PR

Matthew Walls, CEO


Paul Foulger, CFO




Stifel Nicolaus Europe Limited (Nomad and Joint Broker)

Tel: +44 (0)20 7710 7600

Alex Price / Ben Maddison / Richard Short




Cenkos Securities Plc (Joint Broker)

Tel: +44 (0)20 7397 8900

Giles Balleny


Dale Bellis / Michael Johnson (Sales)




Walbrook PR Limited

Tel: 020 7933 8780 or

Anna Dunphy / Louis Ashe-Jepson / Phillip Marriage



About GENinCode

GENinCode Plc is a UK based company specialising in genetic risk assessment of cardiovascular disease. Cardiovascular disease and Ovarian Cancer, two leading causes of death and disability worldwide.


GENinCode operates business units in the UK, in the United States through GENinCode U.S. Inc and in Europe through GENinCode S.L.U.


GENinCode predictive technology provides patients and physicians with globally leading preventative care and treatment strategies. GENinCode CE marked invitro-diagnostic molecular tests combine clinical algorithms and bioinformatics to provide advanced patient risk assessment to predict disease onset.


About Ovarian Cancer

Ovarian cancer is disease that originates in the ovaries, or in the related areas of the fallopian tubes and the peritoneum. Women have two ovaries that are located in the pelvis, one on each side of the uterus. The ovaries make female hormones and produce eggs for reproduction. Women have two fallopian tubes that are a pair of long, slender tubes on each side of the uterus. Eggs pass from the ovaries through the fallopian tubes to the uterus. The peritoneum is the tissue lining that covers organs in the abdomen. Some mutations (changes) in certain genes e.g. in BRCA1 and BRCA2 can increase your risk of developing ovarian cancer.


When ovarian cancer is found in its early stages, long term survival is improved due to more complete tumour resection and more effective treatment. Ovarian cancer is difficult to diagnose through symptom presentation, as the symptoms are vague and present very often only when the cancer has spread beyond the ovaries.


Ovarian cancer ranks fifth in cancer deaths among women, accounting for more deaths than any other cancer of the female reproductive system. The American Cancer Society estimates for ovarian cancer in the United States for 2022 are:


· Approximately 19,880 women will receive a new diagnosis of ovarian cancer.

· Approximately 12,810 women will die from ovarian cancer.


A woman's risk of ovarian cancer during her lifetime is about 1 in 78. Her lifetime chance of dying from ovarian cancer is about 1 in 108. Ovarian cancer mainly develops in older women. About half of the women who are diagnosed with ovarian cancer are 63 years or older. It is more common in white women than African American women. The rate at which women are diagnosed with ovarian cancer has been slowly falling over the past 20 years.

The ROCA Test offers surveillance for women with a BRCA1 or BRCA2 mutation who are not ready to undertake risk reducing surgery. To read more about the ROCA Test, click


About Cardiovascular Disease

Cardiovascular disease (CVD) is the leading cause of death globally, taking an estimated 17.9 million lives each year. CVD is a group of disorders of the heart and blood vessels and include coronary heart disease, cerebrovascular disease, rheumatic heart disease and other conditions. More than four out of five CVD deaths are due to heart attacks and strokes, and one third of these deaths occur prematurely in people under 70 years of age.


The most important behavioural risk factors of heart disease and stroke are unhealthy diet, physical inactivity, tobacco use and harmful use of alcohol. The effects of behavioural risk factors may show up in individuals as raised blood pressure, raised blood glucose, raised blood lipids, and overweight and obesity. These "intermediate risks factors" can be measured in primary care facilities and indicate an increased risk of heart attack, stroke, heart failure and other complications.


Cessation of tobacco use, reduction of salt in the diet, eating more fruit and vegetables, regular physical activity and avoiding harmful use of alcohol have been shown to reduce the risk of cardiovascular disease. Health policies that create conducive environments for making healthy choices affordable and available are essential for motivating people to adopt and sustain healthy behaviours.


Identifying those at highest risk of CVDs and ensuring they receive appropriate treatment can prevent premature deaths. Access to noncommunicable disease medicines and basic health technologies in all primary health care facilities is essential to ensure that those in need receive treatment and counselling.


CVD causes a quarter of all deaths in the UK and is the largest cause of premature mortality in deprived areas and is the single biggest area where the NHS can save lives over the next 10 years. CVD is largely preventable, through lifestyle changes and a combination of public health and NHS action on smoking and tobacco addiction, obesity, tackling alcohol misuse and food reformulation.


Genetic risk assessment can help early detection and treatment of CVD to help patients live longer, healthier lives. Many people are still living with undetected, high-risk conditions such as high blood pressure, raised cholesterol, and atrial fibrillation (AF). Progress continues in the NHS to identify and diagnose people routinely knowing their 'ABC' (testing and monitoring of AF, Blood pressure and Cholesterol) set out in the NHS 10 Year plan.

















This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Date   Source Headline
27th Jun 20244:02 pmRNSResult of AGM
5th Jun 20245:17 pmRNSPosting of Annual Report and Notice of AGM
3rd Jun 20247:00 amRNSFinal Results
23rd May 20247:00 amRNSNotice of Results
1st May 20247:00 amRNSCARDIO inCode-Score presentation
26th Apr 20242:30 pmRNSGrant of Options & Surrender of Existing Options
4th Apr 202410:44 amRNSCARDIO inCode-Score® US study publication
21st Mar 202410:58 amRNSNew NICE Guidance for Ovarian Cancer
9th Feb 202410:00 amRNSHolding(s) in Company
15th Jan 20247:00 amRNSHolding(s) in Company
11th Jan 20242:49 pmRNSHolding(s) in Company
11th Jan 20242:30 pmRNSHolding(s) in Company
9th Jan 20241:30 pmRNSResult of GM and Total Voting Rights
28th Dec 20237:00 amRNSResult of Retail Offer
21st Dec 20236:25 pmRNSResult of Placing and Subscription
21st Dec 20234:59 pmRNSRetail Offer
21st Dec 20234:55 pmRNSPlacing and Subscription
29th Nov 20237:10 amRNSCARDIO inCode-Score 510(k) FDA submission update
29th Nov 20237:00 amRNSChange of Adviser
12th Oct 20237:00 amRNSShareSoc investor presentation
20th Sep 20237:00 amRNSHalf-year Report
13th Sep 20237:00 amRNSNotice of Results
30th Aug 20237:00 amRNSPresentation at European Society of Cardiology
16th Aug 202310:27 amRNSCARDIO inCode 510k filing
19th Jul 20237:00 amRNSCollaboration with US healthcare provider
30th Jun 20234:03 pmRNSResult of AGM
8th Jun 20231:31 pmRNSNotice of AGM and posting of Annual Report
6th Jun 20237:00 amRNSFinal Results
5th Jun 20237:00 amRNSNotice of Results
22nd May 20237:00 amRNSCARDIO inCode be presented at conference
15th May 20237:00 amRNSCollaboration with University Clinic Dresden
2nd May 20237:00 amRNSNHS LIPID inCode testing implementation
3rd Apr 20237:00 amRNSCARDIO InCode CPT PLA Code
13th Mar 20237:00 amRNSStatement re: Silicon Valley Bank
3rd Jan 20234:40 pmRNSSecond Price Monitoring Extn
3rd Jan 20234:35 pmRNSPrice Monitoring Extension
3rd Jan 20237:00 amRNSApproval of California state license
22nd Nov 20222:07 pmRNSIssue of Share Options
3rd Nov 20227:00 amRNSBritish Medical Journal publication
10th Oct 20226:23 pmRNSHolding(s) in Company
27th Sep 20227:00 amRNSHalf-year report
7th Sep 20227:00 amRNSNotice of results
26th Jul 20227:00 amRNSNHS implementation of Lipid inCode testing
23rd Jun 20222:37 pmRNSResult of AGM
23rd May 20224:06 pmRNSPosting of Annual Report and Notice of AGM
17th May 20227:00 amRNSFinal Results
3rd May 20227:00 amRNSNotice of Results
6th Apr 20227:00 amRNSDirector Appointment
23rd Mar 20227:00 amRNSIndiana University Medical School collaboration
15th Mar 20227:00 amRNSLipid inCode pilot

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.